New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo

被引:16
作者
Brizzi, Antonella [1 ]
Brizzi, Vittorio [1 ]
Cascio, Maria Grazia [2 ]
Corelli, Federico [1 ]
Guida, Francesca
Ligresti, Alessia [2 ]
Maione, Sabatino
Martinelli, Adriano [3 ]
Pasquini, Serena [1 ]
Tuccinardi, Tiziano [3 ,4 ]
Di Marzo, Vincenzo [2 ]
机构
[1] Univ Siena, Dipartimento Farm Chim Tecnol, I-53100 Siena, Italy
[2] CNR, Ist Chim Biomol, Endocannabinoid Res Grp, I-80078 Naples, Italy
[3] Univ Pisa, Dipartimento Sci Farmaceut, I-56126 Pisa, Italy
[4] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA
关键词
CARDIOMETABOLIC RISK-FACTORS; ENDOCANNABINOID SYSTEM; FORMALIN TEST; MOLECULAR CHARACTERIZATION; SCORING PROPERTIES; SMOKING-CESSATION; LYSINE RESIDUE; BRAIN; ANALOGS; BINDING;
D O I
10.1021/jm8016255
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Bearing in mind the pharmacophoric requirements of both (-)-trans-Delta(9)-tetrahydrocannabinol (THC) and anandamide (AEA), we designed a novel pharmacophore consisting of both a rigid aromatic backbone and a flexible chain with the aim to develop a series of stable and potent ligands of cannabinoid receptors. In this paper we report the synthesis, docking studies, and structure-activity relationships of new resorcinol-anandamide "hybrids" differing in the side chain group. Compounds bearing a 2-methyloctan-2-yl group at position 5 showed a significantly higher affinity for cannabinoid (CB) receptors, in particular when an alkyloxy chain of 7 or 10 carbon atoms was also present at position 1. Derivative 32 was a potent CB(1) and CB(2) ligand, with K(i) values similar to that of WIN 55-212 and potent antinociceptive activity in vivo. Moreover, derivative 38, although less potent, proved to be the most selective ligand for CB, receptor (K(i)(CB(1)) = 1 mu M, K(i)(CB(2)) = 35 nM).
引用
收藏
页码:2506 / 2514
页数:9
相关论文
共 60 条
[1]   THE FORMALIN TEST - SCORING PROPERTIES OF THE FIRST AND 2ND PHASES OF THE PAIN RESPONSE IN RATS [J].
ABBOTT, FV ;
FRANKLIN, KBJ ;
WESTBROOK, RF .
PAIN, 1995, 60 (01) :91-102
[2]   NEUROBIOLOGY OF MARIJUANA ABUSE [J].
ABOOD, ME ;
MARTIN, BR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (05) :201-206
[3]   Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: Results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers [J].
Addy, Carol ;
Li, Susie ;
Agrawal, Nancy ;
Stone, Julie ;
Majumdar, Anup ;
Zhong, Ling ;
Li, Hankun ;
Yuan, Jinyu ;
Maes, Andrea ;
Rothenberg, Paul ;
Cote, Josee ;
Rosko, Kim ;
Cummings, Corinne ;
Warrington, Steven ;
Boyce, Malcolm ;
Gottesdiener, Keith ;
Stoch, Aubrey ;
Wagner, John .
JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (04) :418-427
[4]  
BARTH F, 1995, Patent No. 656354
[5]  
Barth F., 1997, US Pat. Appl., Patent No. 5624941
[6]   Functional role of high-affinity anandamide transport, as revealed by selective inhibition [J].
Beltramo, M ;
Stella, N ;
Calignano, A ;
Lin, SY ;
Makriyannis, A ;
Piomelli, D .
SCIENCE, 1997, 277 (5329) :1094-1097
[7]  
Benito C, 2003, J NEUROSCI, V23, P11136
[8]   Conformational analysis of N-arachidonylethanolamide (anandamide) using nuclear magnetic resonance and theoretical calculations [J].
Bonechi, C ;
Brizzi, A ;
Brizzi, V ;
Francioli, M ;
Donati, A ;
Rossi, C .
MAGNETIC RESONANCE IN CHEMISTRY, 2001, 39 (08) :432-+
[9]   Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors [J].
Brizzi, A ;
Brizzi, V ;
Cascio, MG ;
Bisogno, T ;
Sirianni, R ;
Di Marzo, V .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) :7343-7350
[10]  
BRIZZI A, 2006, 90769 OCACTPCT